GlassScriptPhysician profile
Sylvia S Cunningham
NPI 1881669430
$1,834.34
in general payments reported to CMS, 2019-2025
23 companies · $563 in 2025
The $563 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $408 · 2022: $236 · 2023: $176 · 2024: $452 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $520.19 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $190.16 | 2021-2025 | |
| Pfizer INC. | $147.58 | 2021-2025 | |
| Abbott Laboratories | $132.51 | 2023-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $116.01 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $105.38 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $73.74 | 2021-2025 | Arexvy, Shingrix |
| Astellas Pharma US INC | $59.14 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.38 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.06 | 2021-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $41.14 | 2022-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $41.10 | 2024-2025 | |
| Shield Therapeutics INC | $37.78 | 2023-2024 | Accrufer |
| Janssen Pharmaceuticals, INC | $35.30 | 2021 | |
| Medtronic, INC. | $34.92 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $31.73 | 2021 | |
| Esperion Therapeutics, INC. | $30.83 | 2021-2024 | Nexletol |
| Lilly USA, LLC | $28.99 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $26.37 | 2021-2023 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $24.27 | 2022 | |
| Saluda Medical Americas, INC. | $23.11 | 2025 | Evoke |
| Bayer Healthcare Pharmaceuticals INC. | $19.46 | 2021 | |
| Nevro Corp. | $17.19 | 2024 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.